Ken Lock

Ken Lock serves as the Chief Commercial Officer at Sling Therapeutics since June 2025. Previously, Ken held the same position at ACELYRIN, INC., where responsibilities included leading commercial and medical affairs amid the company's merger with Alumis, and overseeing the launch of key therapeutic products. Prior to that, Ken was the Chief Commercial Officer at Arcutis Biotherapeutics, Inc., responsible for launching ZORYVE® for Plaque Psoriasis in the US and Canada. Ken's extensive experience also includes significant roles at Gilead Sciences, Amgen, Pfizer, and Biogen Idec, spanning marketing, sales leadership, and organizational development in various therapeutic areas. Ken holds an MBA in Marketing and Strategy from Cornell Johnson Graduate School of Management and dual Bachelor Degrees in Biochemistry and Cell Biology, and Psychology from UC San Diego.